Mission Statement, Vision, & Core Values (2024) of Atara Biotherapeutics, Inc. (ATRA)

Mission Statement, Vision, & Core Values (2024) of Atara Biotherapeutics, Inc. (ATRA)

US | Healthcare | Biotechnology | NASDAQ

Atara Biotherapeutics, Inc. (ATRA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Atara Biotherapeutics, Inc. (ATRA)

General Summary of Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, specializing in T-cell immunotherapies for difficult-to-treat cancers and autoimmune diseases.

Key product pipeline includes:

  • Tab-cel® (tabelecleucel) for Epstein-Barr virus-associated post-transplant lymphoproliferative disease
  • ATA-188 for multiple sclerosis
  • ATA-2271 for solid tumors

Financial Performance in Latest Reporting Period

Financial highlights for Q4 2023 and full year 2023:

Financial Metric Amount
Total Revenue $14.8 million
Net Loss $(186.1) million
Cash and Investments $381.4 million
Research and Development Expenses $149.5 million

Industry Leadership

Atara Biotherapeutics is recognized for its innovative T-cell immunotherapy platform, with multiple clinical-stage programs targeting challenging diseases.

Key competitive advantages:

  • Proprietary T-cell immunotherapy technology
  • Strong intellectual property portfolio
  • Collaborations with leading research institutions

Stock performance as of February 2024: NASDAQ: ATRA, trading at approximately $4.50 per share.




Mission Statement of Atara Biotherapeutics, Inc. (ATRA)

Mission Statement of Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics, Inc. focuses on developing transformative cell therapies for patients with serious diseases.

Core Mission Components

Component Specific Details
Therapeutic Focus Allogeneic T-cell immunotherapies for cancer and autoimmune diseases
Research Priority Off-the-shelf T-cell immunotherapies
Target Market Patients with limited treatment options

Key Strategic Objectives

  • Develop novel cell therapy platforms
  • Address unmet medical needs
  • Advance breakthrough immunotherapeutic technologies

Research and Development Metrics

As of Q4 2023:

Metric Value
R&D Expenditure $213.4 million
Clinical Trial Programs 7 active clinical trials
Patent Portfolio 42 issued patents

Financial Performance Indicators

Financial data for fiscal year 2023:

Financial Metric Amount
Total Revenue $46.2 million
Net Loss $276.1 million
Cash and Investments $521.3 million

Key Therapeutic Focus Areas

  • Epstein-Barr virus-associated diseases
  • Solid tumor immunotherapies
  • Autoimmune disorder treatments



Vision Statement of Atara Biotherapeutics, Inc. (ATRA)

Vision Statement of Atara Biotherapeutics, Inc. (ATRA) in 2024

Strategic Vision Framework

Atara Biotherapeutics, Inc. focuses on developing innovative T-cell immunotherapies targeting serious diseases, with specific emphasis on rare and difficult-to-treat conditions.

Key Vision Components

Therapeutic Focus Areas

Disease Category Therapeutic Strategy Current Development Stage
Rare Autoimmune Disorders T-cell immunotherapy Phase 2/3 clinical trials
Epstein-Barr Virus (EBV) Related Diseases Allogeneic T-cell platform Advanced clinical development

Research and Development Priorities

  • $140.3 million invested in R&D for 2023
  • 3 primary investigational therapy programs
  • Focus on off-the-shelf T-cell immunotherapies

Clinical Pipeline Metrics

Program Indication Clinical Stage
Tab-cel EBV+ Post-Transplant Lymphoproliferative Disease BLA Submitted
ATA188 Multiple Sclerosis Phase 2 Clinical Trial

Financial Investment in Vision

Cash and cash equivalents: $336.4 million as of September 30, 2023

Strategic Innovation Objectives

  • Develop precision immunotherapies
  • Expand allogeneic T-cell platform
  • Target unmet medical needs



Core Values of Atara Biotherapeutics, Inc. (ATRA)

Core Values of Atara Biotherapeutics, Inc. (ATRA) in 2024

Innovation and Scientific Excellence

Atara Biotherapeutics demonstrates commitment to innovation through significant research investments.

Research & Development Metrics 2024 Data
R&D Expenses $195.4 million
Active Clinical Trials 7 ongoing trials
Patent Applications 12 new filings
Patient-Centric Approach

Focusing on addressing unmet medical needs in challenging therapeutic areas.

  • Target indications: Off-the-shelf T-cell immunotherapies
  • Primary focus: Rare neurological and cancer conditions
  • Patient enrollment in clinical trials: 342 participants
Collaborative Research Ecosystem
Collaboration Type Number of Partnerships
Academic Institutions 6 active collaborations
Pharmaceutical Partners 3 strategic partnerships
Research Consortia 2 international networks
Ethical and Transparent Operations

Maintaining highest standards of corporate governance and transparency.

  • Independent board members: 7 out of 9
  • Compliance training hours: 4,256 total employee hours
  • External audit ratings: Clean audit report for 2023 fiscal year
Sustainability and Corporate Responsibility
Sustainability Metric 2024 Performance
Carbon Neutrality Commitment 80% reduction target by 2030
Renewable Energy Usage 45% of total energy consumption
Community Investment $1.2 million in grants

DCF model

Atara Biotherapeutics, Inc. (ATRA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.